I remember meeting Sir Henry Dale and telling him about our work with dopamine. He had studied the amine in 1910, and he told me that he had found dopamine unusual at that time.
We have studied dopamine for many years, and there have been a number of collaborators, although my name is the only one on this paper. We felt that it had clinical application, but the pharmaceutical firms we contacted were not interested in developing dopamine for use by the practising physician. Then Dr John Zaroslinski and I met and he became very interested. That is how Arnar-Stone got involved in the development of dopamine. Maryland. I studied dopamine because a bio-chc_inist asked me whether I could differentiate dopamine from norepinephrine in the dog. I therefore compared the two amines in a dog preparation, with a strain gauge to measure cardiac contractile force and with recordings of heart rate and blood pressure. As is shown in Fig 1, which is from a paper co-authored with Dr Robert McDonald (McDonald & Goldberg 1963 ) an interesting dose response phenomenon was observed. With the injection of 2 ,ug/kg of dopamine there was a reduction in diastolic pressure. At this time there was no change in heart rate and only a slight increase in cardiac contractile force. As the dose was increased there was a further increase in cardiac contractility, and the diastolic pressure started to rise. This, as we later found, was due to an alpha adrenergic effect. At these large doses dopamine effects resemble those of norepinephrine. However, the initial decrease in blood pressure was unexplained, since it was not blocked by beta adrenergic blocking agents. A vasodilating action of dopamine had been reported in the 1940s by Holtz and his colleagues (Holtz & Credner 1942) , but the mechanism of this reduction in pressure was DOSE not clear. We decided, after further animal studies, that the cardiovascular effects of dopamine should be investigated in man. We wanted to see what would happen in the dose range which either decreased or did not increase arterial blood pressure. We were most interested in the fact that in the dog, heart rate did not increase even though there was a reduction in blood pressure. We then found that intravenous infusions of dopamine in man, at infusion rates ranging from 2 to approximately 10 ,ug/kg/min, produced pronounced increments in the cardiac index without affecting heart rate or diastolic arterial blood pressure. Thus, the response to dopamine in normal human subjects appeared to GFR im in. be similar to that observed in aneesthetized dogs (Horwitz et al. 1962 , McDonald et al. 1964 ).
On the basis of this investigation, we decided to study the effects of dopamine in patients with congestive heart failure (McDonald et al. 1964 , Goldberg et al. 1963 . Our concept was that if dopamine could increase cardiac output without increasing peripheral resistance or altering heart rate, then it should be beneficial in this condition. Clearly, the infusion rate had to be closely controlled to prevent an increase in pressure and heart rate. When I went to Emory University we studied several patients with congestive heart failure ( Fig 2) . In our first study, a patient with severe congestive heart failure was brought into a UKV Fig metabolic unit for study. The patient was not responsive to the diuretics available at that time.
We placed him on a constant sodium diet and found that he was excreting less than 5 mEq in 24 hours. After a period in hospital, his sodium excretion was constant. We then administered dopamine at a relatively slow rate, about 1-2 ,ug/ kg/min, for a period of several hours, and observed a good diuresis in that sodium excretion increased to about 45 mEq/24 hours. We then had several control days, including one day in which we administered glucose and water without noting an increase in sodium excretion. We later tried the effect of half the dose of dopamine, and also repeated the full dose, and found that sodium excretion was related to the dose of drug administered.
At the conclusion of this study, we felt that dopamine was simply causing diuresis by causing an increase in cardiac outputa mechanism similar to that postulated for digitalis. We therefore reasoned that if this were the case, dopamine should do nothing to sodium excretion or renal function in normal subjects (McDonald et al. 1964) . Fig 3 shows the results of studies in normal subjects. When dopamine was administered at infusion rates which did not change arterial blood pressure or heart rate there was the expected increase in cardiac index. But there was also an increase in renal blood flow and sodium excretion. The increase in renal blood flow without any change in arterial pressure indicated that the drug must be decreasing renal vascular resistance.
On the basis of these results we went back to experiments in dogs to see if we could learn more about the reduction in renal vascular resistance (McNay et al. 1963 (McNay et al. , 1965 McNay & Goldberg 1966) . We applied an electromagnetic flow meter to the renal artery, inserted a small needle into the artery for the injection of drugs, and measured blood pressure and renal blood flow. The results, which are shown in Fig 4, were an increase in renal blood flow, with no change in pressure, indicating that there was a decrease in vascular resistance. The increase in renal blood flow which occurred with an injection of 1.5 ,ug of dopamine gave place, as the dose was increased, to a biphasic effect, with vasoconstriction preceding the vasodilation. This is the alpha adrenergic action of dopamine; with very large doses, vasoconstriction can totally override vasodilation.
We then tried to determine the mechanism of the vasodilation. We found it was not blocked by adrenergic blocking agents, cholinergic blocking agents, or antihistamines (Goldberg 1972). About 4-5 years later, we found that vasodilation produced by dopamine was selectively attenuated by phenothiazines, such as chlorpromazine (Goldberg & Yeh 1971) , and by butyrophenones, such as haloperidol (Yeh et al. 1969 ).
Another interesting phenomenon was that we could not demonstrate similar vasodilation in certain other vascular beds ( Fig 5) . In the femoral vascular bed of the dog, only vasoconstriction was observed, and this effect was blocked by phenoxybenzamine. After phenoxybenzamine much larger doses, of dopamine than those needed to vasodilate the kidney did cause vasodilation in the skeletal muscle vascular bed (McNay & Goldberg 1966 ) and this effect was attenuated by propranolol. Later, as Dr Zaroslinski mentioned, Eble found a dopamine-like effect in the mesenteric arterial vascular bed of the dog (Eble 1964), and others have described the phenomenon in the intracerebral vessels (von Essen 1972).
More recently, Dr N Toda and I found that we could demonstrate a relaxing effect of dopamine in isolated renal and mesenteric arteries of the dog (Goldberg & Toda 1975) . In this preparation, the artery was first contracted with prostaglandin F, and then treated with phenoxybenzamine to block the vasoconstriction; then, after application of dopamine, relaxation was observed. We have continued to study the unusual renal and mesenteric vasodilation, and now feel that it is due to the action of dopamine on a specific receptor. Our reason for this conclusion is that the structure/activity relationship for this phenomenon is different from that for any other receptor (Goldberg et al. 1968 , Crumly & Goldberg 1976 ) and because the dilation is selectively attenuated by butyrophenones and phenothiazines. It is interesting that active analogues also apparently activate the dopamine receptors in the caudate nucleus, and that phenothiazines and butyrophenones are antagonists of dopamine in that area (Iverson 1975 , Goldberg 1975 Further studies are being carried out in our laboratories and elsewhere to establish this point. After we had completed our studies demonstrating the efficacy of dopamine in congestive heart failure, it occurred to us that dopamine might be useful in the treatment of shock. At that time isoproterenol was the primary drug used, and we set up experiments in dogs in which we compared the effects of dopamine and isoproterenol on renal blood flow, blood pressure and cardiac contractile force (Goldberg 1975) . Fig 6 illustrates the effects of an infusion of isoproterenol at a rate of 0.24 ug/kg/min and of dopamine at a rate of 3.6 ,ug/kg/min. In these dose ranges the two drugs had approximately the same effects on blood pressure and cardiac contractile force. However, dopamine increased renal blood flow and isoproterenol did not. The postulated reason is that isoproterenol diverts increased blood flow to the skeletal muscle and mesenteric vascular bed, while dopamine constricts the skeletal muscle vascular bed, and renal blood flow is usually increased. Fig 7 illustrates the effects of dopamine in a patient in shock studied many years ago (Mac-Cannell et al. 1966 ). This patient had septic shock and, as shown in Fig 7, her blood pressure was about 70/50 mmHg. The pressure remained low for s-everal hours and there was no urine flow. Now a very important clinical pointdopamine was not administered until we were assured that there was adequate plasma volume expansion. At that time dextran was in general use, and this volume expander was therefore given until the central venous pressure was considered adequate. Today we use saline for increasing plasma volume, and regulate its administration by use of pulmonary wedge pressure measurements. As shown in the figure, there was an increase in systemic arterial pressure and a slight increase in cardiac output following dextran. When dopamine was administered, blood pressure and cardiac output increased further, and urine flow also increased. It was not possible, however, to determine whether the increase in urine flow was due to renal vasodilation or to the increase in blood pressure with consequent increase in renal blood flow. In some other patients. however, there was no change in perfusion pressure when dopamine was administered, right up until the diuresis occurred. 
Fig 8 illustrates a study in a patient after cardiopulmonary bypass surgery. She was virtually anuric for at least 24 hours. Metaraminol, mannitol and epinephrine had already been administered without benefit. Epinephrine increased the blood pressure slightly, but there was no increase in urine flow. After epinephrine had been discontinued dopamine was started, and although the pressure was not changed there was a well-marked diuresis. Thus a diuresis was obtained with dopamine without necessarily increasing blood pressure. This is an interesting phenomenon which we would like to explore further.
Finally, it is possible that dopamine might be useful in the treatment of hypertensive patients. Fig 9 illustrates the intravenous administration of dopamine to a patient with hypertension being treated with guanethidine. Dopamine alone caused a pronounced increase in arterial pressure. However, after administration of phenoxybenzamine, 1 mg/kg, the vasoconstriction was blocked and there was a pronounced reduction in arterial pressure with the patient in the supine position. As you know, it is difficult to lower blood pressure with most antihypertensive drugs with the patient in the supine position. Preliminary studies with a few patients indicated that despite this marked reduction in arterial pressure renal blood flow was maintained (McNay et al. 1966) .
Professor Dollery may want to discuss his group's study in which dopamine was administered to hypertensive patients for several hours without any lasting improvement in renal blood flow (Orme et al. 1973) . However, these patients were not given phenoxybenzamine. If an oral dopamine-like drug were available and could be given to hypertensive patients before renal vasoconstriction occurred, it might be beneficial in preventing renal deterioration.
To summarize, it is probable that dopamine itself will continue to be a useful drug for the treatment of shock, in which it is important to have a beta adrenergic effect on the heart and an alpha adrenergic effect to raise blood pressure. It is of course very useful to have the dopamineinduced renal vasodilating action as well. If a dopamine-like drug could be developed with only beta adrenergic and renal vasodilating action, this would be better for treating congestive heart failure. If a dopamine-like drug without alpha or beta adrenergic activity were developed it could be useful for treating hypertension. make some comments on the effects of dopamine on cerebral vessels in comparison with other vessels. We have done some experiments with analogues of dopamine such as N,N,dimethyl dopamine and tetrahydronaphthalene, and we confirm your findings, but we have not been able to find any analogues which had a specific dopaminergic receptor action. We have not tested epinine.
Secondly, we find on the rat aorta and the baboon middle cerebral artery in vitro, that dopamine has only alpha constrictor actions, whereas on the baboon basilar artery and on the human basilar artery it has specific vasodilator actions at low doses. Higher doses produce secondary actions which are blocked by phentolamine. I was going to ask you then whether you have found any vessels which have only alpha constrictor actions which are blocked by phentolamine.
The other thing is the difficulty of extrapolating from animals to man, because we find that the baboon middle cerebral artery is constricted by dopamine in vitro, but in vivo it dilates in response to intracisternal dopamine. So there are several difficulties here and I wonder if you could make some comments on them.
Professor Goldberg: I spent a year at Kyoto University in Japan with Dr N Toda, who is an expert on isolated vessels, working on just this phenomenon, and there are a few facts which have to be known about isolated blood vessels. If you remove any blood vessel from the body and put it into a bath, the constrictor effect of drugs is potentiated. This is not restricted to dopamine. If we inject dopamine directly into the renal artery of an intact dog, the first thing we see is vasodilation. If we take the renal artery out of the dog, soak it in a bath and apply dopamine, it contracts. If we then take this blood vessel, apply phenoxybenzamine for one hour, then contract it, say with potassium, or prostaglandin F2 alpha, (not noradrenaline because of the phenoxybenzamine), then we see dose-related relaxation which is not blocked by propranolol. It is worth emphasizing, by the way, that after phenoxybenzamine treatment a blood vessel has no tone, and thus it cannot show relaxation. Many people made the mistake of looking for dopamine-induced relaxation under these conditions, and of course could not demonstrate it because there was no resting tone. You have to give something to make it contract. Now, with respect to the different vessels in different species, there is a species difference, as Dr Zaroslinski mentioned, which was first noted by Dr Holtz in Germany: the guinea-pig's blood pressure dropped, the rat's blood pressure increased. I do not think it has anything to do with presence or absence of dopamine receptors. For example, if one takes the rat and uses phenoxybenzamine, the blood pressure drops and the response resembles that in the guinea-pig. So there is a difference between species, but I am not sure that it has anything to do with dopamine receptors: it is related to alpha sensitivity. Lastly, what about the differences between different vessels? We know that the aorta does not have dopamine receptors; we cannot obtain relaxation in any type of aorta. It is the same in the femoral artery; we cannot show relaxation in the large femoral artery. Interestingly, though, in the isolated small femoral arteries we can see it. So there are great variations, I think, in the distribution of dopamine receptors in different parts of the body, and that is what makes it interesting -why are there dopamine receptors in one place and not others?
Does that answer your question?
Dr Boullin: Yes, very largely. We have to have models for in vivo systems, however, and that is why we have used human cerebral arteries. Also if we cannot extrapolate from animals to man then things are very difficult. I believe it is most important to establish whether differences between in vivo and in vitro results are based on some pharmacological mechanism. For example use of an alpha-blocker may help to unmask specific dopamine vasodilator receptors. I agree with what you say about constrictor actions predominating in vitro and about the absence of dopaminergic vasodilator receptors in the aorta. For me, the vital questions are what is the real distribution of dopaminergic vasodilator receptors on the human cerebral arterial tree? Are they ubiquitous or only on some vessels? And are their sensitivity and distribution affected by disease? We have to try to answer such questions, and it is going to be difficult.
Professor H Groebecker (Frankfurt): I should like to know your opinion, Dr Goldberg, about whether dopamine receptors can be located presynaptically. Is there any evidence?
Professor Goldberg: I guess you are referring to Langer's work. It is very interesting, there seem to be dopamine receptors everywhere. You cannot find any organ that is not reported to have dopamine receptors; I would say 90% of them are not classical receptors. For example, I do not know whether vomiting is due to a specific receptor, as Dr Zaroslinski suggested. A lot of the central nervous system pharmacologists have been using vomiting as a screen, but we do not find any similarity in the structure activity of the vomiting. Now Langer, who is in Argentina, and some people at the Karolinska, observed that if one isolates a sympathetic nerve, measures the amount of norepinephrine coming out of it, and then adds dopamine to the preparation, there was a fall in the amount of norepinephrine coming out when it was stimulated. That is, dopamine is blocking the release of norepinephrine. Is that what you are talking about?
Langer did structure activity of this phenomenon, and it is not like the renal receptor; alpha methyldopamine is active here. However, it could explain a rather interesting phenomenon we have observed. Did you notice that when the blood pressure dropped (in that slide where I showed the dose response curve) there was no reflex tachycardia? I never understood that. It looks as if dopamine has some sort of a nerve-synoptic phenomenon. Perhaps that is the pre-ganglionic effect. It also has some slight ganglionic blocking effect. But how can you drop the blood pressure without reflex tachycardia?
Professor Dollery (Chairman): Is what you say about the differential effect on contractility and heart rate true if you are studying people in shock as opposed to normals? We did a lot of work on the Lilly compound dobutamine, and, in people with fairly normal hearts, we found that that drug had a greater effect on contractility for a given increase in rate than isoprenaline had. However, when we went to the intensive care unit and we studied people four hours after valve replacement, we found that isoprenaline and dobutamine could almost exactly be superimposed in their cardiac output and rate effects.
Professor Goldberg: Yes, it is different. I cannot predict what the rate effect is going to be in a patient in shock. I do not understand why dopamine does not increase the rate more, as I was mentioning earlier. Perhaps it is this nerve phenomenon; the patient in shock does not have this blocking effect. Or it may be something else.
I just want to mention that dobutamine is a new drug which is being studied and I do not think it ought to be confused with dopamine. It is an interesting drug. It is primarily beta,, but it does not dilate the kidneys, it does not have any dopamine receptor activity. They were looking for another dopamine-like drug and this one came up by chance.
Dr Renard (Belgium): I should like to ask if you have any information about the naturetic effect of dopamine.
Professor Goldberg: The naturetic effect of dopamine, in my opinion, is secondary to the renal vasodilation. Many people have shown that if you inject any vasodilator into the kidney, like acetylcholine, or bradykinin, there is naturesis secondary to vasodilation. So I have always assumed that the dopamine effect was secondary to vasodilation too. Dopamine differs from these other drugs in that it is the only one I know that can be given intravenously; you have to inject acetylcholine and these other drugs intraarterially. Other people have suggested that it may have a tubular effect. The evidence is not too good, and recently there has been some work with microspheres to suggest that the renal cortical blood flow is increased, which would also explain the naturesis. That is as much as I know.
Professor Dollery: Perhaps I might make a brief comment myself on the point Dr Goldberg was making apropos of hypertension. We were interested in dopamine in two different contexts in hypertension. One was simply that we were confronted with patients with moderate, or even severe, degrees of renal failure and we wanted to know whether dopamiiie could benefit them by increasing glomerular filtration rate. The result there was quite disappointing. We were able to demonstrate increases in renal blood flow of the same proportion as we had seen in normal people. In other words, we could double or even triple renal blood flow, but this was associated with only rather small changes in glomerular filtration rate. So the idea we had had that we might be able to improve glomerular filtration rate in some of these patients was not sustained during infusions of about 3 days' duration.
The second concept we had in mind arose out of Arthur Guyton's work. You will remember that Guyton assigns a central role in long-term blood pressure regulation to the blood pressure threshold at which the kidney excretes sodium. He says that this is essentially what sets the longterm level of pressure. I am not sure that I entirely agree with him about that, but it obviously is a very important determinant. In theory, if you could use a drug that would reset downwards the level of blood pressure at which the kidney pours out salt and water, that should reset downwards the long-term blood pressure. We did not observe this in these infusions of two or three days' duration. We got a considerable sodium diuresis on the first day, and then a new steady state for the second and third day. Then, when we had to stop the infusion after that time, we got a day or two during which sodium was conserved. We did not observe any hypotensive effect that we could relate to that. The difficulty is that you have to judge the infusion rate rather carefully in these patients. You do not want to put their blood pressure up by the alpha effects. Perhaps really to test this concept, as Dr Goldberg was saying, you would need something that was purely a renal vasodilator and which did not have any alpha and beta effects, and I do not think that we really have that substance yet.
Professor Goldberg: I think that at some point it might be interesting to do it for two or three weeks. I do not know how long it would take to reverse, if it could happen at all. We have given dopamine for as long as two or three weeks to some patients, but I would want if possible to do it to a patient who did not already have nephrosclerosis, and use phenoxybenzamine in addition to dopamine.
The trouble with this kind of work is that one does not like to study a patient who is responding to other things. That is why I think we shall probably have to wait for an orally active agent. It is difficult, in today's climate, to do clinical trials in a patient who is responsive to other drugs. I feel that perhaps we can prevent the renal deterioration, but I do not know.
